Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency
Neil P. Shah(Unknown), Charles L. Sawyers(Memorial Sloan Kettering Cancer Center)
Cited by 415
Related Papers
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
|Cancer Cell|2002|1.6k
Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors
|New England Journal of Medicine|2005|1.4k
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
|The Lancet|2010|1.1k
The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway
|Proceedings of the National Academy of Sciences|1998|691